{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T06:06:46Z","timestamp":1784786806040,"version":"3.55.0"},"reference-count":72,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Prostate cancer is a typical age-associated malignancy, and increasing evidence suggests that age-related immune alterations play an important role in its initiation, progression, and therapeutic response. Immunosenescence, characterized by impaired immune surveillance, reduced effector-cell function, contraction of the na\u00efve T-cell repertoire, and persistent low-grade inflammation, may contribute to the establishment of a tumor-permissive microenvironment in older patients. In prostate cancer, these changes are particularly relevant because the disease often develops in an immunologically \u201ccold\u201d and suppressive tumor milieu. In addition to systemic immune aging, cellular senescence and the senescence-associated secretory phenotype (SASP) further reshape the local microenvironment by promoting chronic inflammation, stromal remodeling, and immune dysfunction. Together, immunosenescence, inflammaging, and senescence-related signaling may facilitate tumor persistence, immune escape, and resistance to therapy. Emerging therapeutic strategies therefore extend beyond tumor-intrinsic targets and include optimization of immunotherapy, reprogramming of the tumor microenvironment, and targeting of senescent cells or SASP-related pathways. A deeper understanding of how aging-related immune dysfunction interacts with prostate cancer biology may help improve patient stratification and support the development of more individualized treatment strategies for older prostate cancer patients.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1852294","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T05:40:32Z","timestamp":1784785232000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunosenescence in prostate cancer: from aging-related immune dysfunction to therapeutic opportunities"],"prefix":"10.3389","volume":"17","author":[{"given":"Juntao","family":"Guo","sequence":"first","affiliation":[{"name":"Department of Urology, Suzhou Ninth People\u2019s Hospital, Soochow University","place":["Suzhou, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Urology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University","place":["Suzhou, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Urology, Suzhou Ninth People\u2019s Hospital, Soochow University","place":["Suzhou, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Urology, Suzhou Ninth People\u2019s Hospital, Soochow University","place":["Suzhou, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Urology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University","place":["Suzhou, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingxiang","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Urology, Suzhou Ninth People\u2019s Hospital, Soochow University","place":["Suzhou, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/478126","article-title":"Senescent remodeling of the innate and adaptive immune system in the elderly men with prostate cancer","volume":"2014","author":"Taverna","year":"2014","journal-title":"Curr Gerontol Geriatr Res"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1159\/000541881","article-title":"The immune microenvironment in prostate cancer: a comprehensive review","volume":"103","author":"Novysedlak","year":"2025","journal-title":"Oncology"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s10522-017-9682-z","article-title":"Immunosenescence and cancer","volume":"18","author":"Pawelec","year":"2017","journal-title":"Biogerontology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s13045-020-00986-z","article-title":"Immunosenescence: a key player in cancer development","volume":"13","author":"Lian","year":"2020","journal-title":"J Hematol Oncol J Hematol Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/s41392-025-02371-z","article-title":"Immunosenescence: signaling pathways, diseases and therapeutic targets","volume":"10","author":"Fu","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01960","article-title":"Immunosenescence and inflamm-aging as two sides of the same coin: friends or foes","volume":"8","author":"Fulop","year":"2017","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22137016","article-title":"Immune aging and immunotherapy in cancer","volume":"22","author":"Kaiser","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B8","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s12964-025-02082-6","article-title":"Immunosenescence promotes cancer development: from mechanisms to treatment strategies","volume":"23","author":"Wang","year":"2025","journal-title":"Cell Commun Signal CCS"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1421062","article-title":"Age-associated changes in innate and adaptive immunity: role of the gut microbiota","volume":"15","author":"Gao","year":"2024","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s00391-025-02496-4","article-title":"Age-associated changes of the immune system: immunosenescence and effects on vaccinations","volume":"58","author":"Weinberger","year":"2025","journal-title":"Z Gerontol Geriatr"},{"key":"B11","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.exger.2017.10.024","article-title":"Age and immunity: what is \u2018immunosenescence\u2019","volume":"105","author":"Pawelec","year":"2018","journal-title":"Exp Gerontol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2025.2477300","article-title":"Age-related changes in the immune system and challenges for the development of age-specific vaccines","volume":"57","author":"Doherty","year":"2025","journal-title":"Ann Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/S0034-8376(25)00212-8","article-title":"The role of immunosenescence in the development of age-related diseases","volume":"68","author":"F\u00fcl\u00f6p","year":"2016","journal-title":"Rev Investig Clin Organo Hosp Enfermedades Nutr"},{"key":"B14","article-title":"Aging, immunity, and cancer","volume":"11","author":"Fulop","year":"2011","journal-title":"Discov Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0366-6999.2012.18.023","article-title":"Senescent remodeling of the immune system and its contribution to the predisposition of the elderly to infections","volume":"125","author":"Dewan","year":"2012","journal-title":"Chin Med J (Engl)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-020-00813-0","article-title":"Mitochondria, immunosenescence and inflammaging: a role for mitokines","volume":"42","author":"Conte","year":"2020","journal-title":"Semin Immunopathol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/s41392-023-01502-8","article-title":"Inflammation and aging: signaling pathways and intervention therapies","volume":"8","author":"Li","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/cells10102562","article-title":"Inflammaging, an imbalanced immune response that needs to be restored for cancer prevention and treatment in the elderly","volume":"10","author":"Serrano-L\u00f3pez","year":"2021","journal-title":"Cells"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2024.102540","article-title":"Immunosenescence and inflammaging: mechanisms and role in diseases","volume":"101","author":"Ajoolabady","year":"2024","journal-title":"Ageing Res Rev"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.2147\/IJGM.S435001","article-title":"Immunotherapy in older patients with cancer: a narrative review","volume":"17","author":"Smith","year":"2024","journal-title":"Int J Gen Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.bj.2020.07.009","article-title":"Immunotherapy in older patients with cancer","volume":"44","author":"Granier","year":"2021","journal-title":"BioMed J"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-017-0006-x","article-title":"The twilight of immunity: emerging concepts in aging of the immune system","volume":"19","author":"Nikolich-\u017dugich","year":"2018","journal-title":"Nat Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01618","article-title":"The changing landscape of naive T cell receptor repertoire with human aging","volume":"9","author":"Egorov","year":"2018","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/s41391-021-00340-5","article-title":"How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer","volume":"24","author":"Stultz","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2013.05.016","article-title":"Impact of aging on antigen presentation cell function of dendritic cells","volume":"25","author":"Wong","year":"2013","journal-title":"Curr Opin Immunol"},{"key":"B26","article-title":"Role of CD8 T cell replicative senescence in human aging and in HIV-mediated immunosenescence","volume":"2","author":"Dock","year":"2011","journal-title":"Aging Dis"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s11357-014-9729-x","article-title":"Ageing and myeloid-derived suppressor cells: possible involvement in immunosenescence and age-related disease","volume":"36","author":"Bueno","year":"2014","journal-title":"Age"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2223-4683.2015.04.12","article-title":"Inflammation in prostate cancer progression and therapeutic targeting","volume":"4","author":"Stark","year":"2015","journal-title":"Transl Androl Urol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.2165\/00129785-200101040-00001","article-title":"Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor","volume":"58","author":"Hobisch","year":"1998","journal-title":"Cancer Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16213685","article-title":"Deciphering the tumor microenvironment in prostate cancer: a focus on the stromal component","volume":"16","author":"Pakula","year":"2024","journal-title":"Cancers"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S32839","article-title":"The tumor microenvironment in prostate cancer: elucidating molecular pathways for therapy development","volume":"4","author":"Corn","year":"2012","journal-title":"Cancer Manag Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000000719","article-title":"Understanding the tumor-immune microenvironment in prostate cancer","volume":"33","author":"Dong","year":"2021","journal-title":"Curr Opin Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-024-00825-z","article-title":"Targeting the tumor microenvironment, a new therapeutic approach for prostate cancer","volume":"28","author":"Fang","year":"2025","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/biom15060826","article-title":"Role of tumor microenvironment in prostate cancer immunometabolism","volume":"15","author":"Wang","year":"2025","journal-title":"Biomolecules"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2025.2595788","article-title":"Prostate tumor immune microenvironment changes following immunotherapy shared by patients who developed anti-tumor response or immune-related adverse events","volume":"14","author":"Rastogi","year":"2025","journal-title":"Oncoimmunology"},{"key":"B36","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s10238-025-01944-0","article-title":"Tumor microenvironment-mediated immune evasion and resistance in prostate cancer: mechanisms, cross-talk, and therapeutic opportunities","volume":"26","author":"Li","year":"2025","journal-title":"Clin Exp Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1398109","article-title":"Immunome profiling in prostate cancer: a guide for clinicians","volume":"15","author":"San-Jose Manso","year":"2024","journal-title":"Front Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26199777","article-title":"Molecular landscape of prostate cancer across age groups: impact on prognosis and treatment outcomes","volume":"26","author":"Orzechowska","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16183215","article-title":"Evidence of the link between stroma remodeling and prostate cancer prognosis","volume":"16","author":"Vecchiotti","year":"2024","journal-title":"Cancers"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1663396","article-title":"Characteristics of tertiary lymphoid structures in prostate cancer and the impact of neoadjuvant therapy on their formation and maturation","volume":"16","author":"Liu","year":"2025","journal-title":"Front Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1395047","article-title":"A new perspective on prostate cancer treatment: the interplay between cellular senescence and treatment resistance","volume":"15","author":"Xu","year":"2024","journal-title":"Front Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-018-0059-4","article-title":"Inflammaging: a new immune-metabolic viewpoint for age-related diseases","volume":"14","author":"Franceschi","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13045-023-01426-4","article-title":"Aging microenvironment and antitumor immunity for geriatric oncology: the landscape and future implications","volume":"16","author":"Zhao","year":"2023","journal-title":"J Hematol Oncol J Hematol Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3109\/00313025.2010.508791","article-title":"The senescence pathway in prostatic carcinogenesis","volume":"42","author":"Sharma","year":"2010","journal-title":"Pathol (Phila)"},{"key":"B45","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s13578-022-00941-0","article-title":"Distinct mechanisms mediating therapy-induced cellular senescence in prostate cancer","volume":"12","author":"Kallenbach","year":"2022","journal-title":"Cell Biosci"},{"key":"B46","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/s41585-021-00496-8","article-title":"Cellular senescence as a possible link between prostate diseases of the ageing male","volume":"18","author":"Fiard","year":"2021","journal-title":"Nat Rev Urol"},{"key":"B47","article-title":"p16\/pRb pathway alterations are required for bypassing senescence in human prostate epithelial cells","volume":"59","author":"Jarrard","year":"1999","journal-title":"Cancer Res"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1007\/s10565-010-9163-5","article-title":"Snail regulates cell survival and inhibits cellular senescence in human metastatic prostate cancer cell lines","volume":"26","author":"Emadi Baygi","year":"2010","journal-title":"Cell Biol Toxicol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ccell.2020.10.012","article-title":"Senescence reprogramming by TIMP1 deficiency promotes prostate cancer metastasis","volume":"39","author":"Guccini","year":"2021","journal-title":"Cancer Cell"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-023-00827-x","article-title":"Prognostic and therapeutic potential of senescent stromal fibroblasts in prostate cancer","volume":"21","author":"Mori","year":"2024","journal-title":"Nat Rev Urol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.semcancer.2025.01.001","article-title":"Mechanisms and strategies of immunosenescence effects on non-small cell lung cancer (NSCLC) treatment: A comprehensive analysis and future directions","volume":"109","author":"Zhou","year":"2025","journal-title":"Semin Cancer Biol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1656733","article-title":"Senescent immune cells in the tumor microenvironment: emerging insights into cancer immunotherapy resistance","volume":"16","author":"Gao","year":"2025","journal-title":"Front Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2025.07.022","article-title":"Immunoregulatory mechanisms in the aging microenvironment: Targeting the senescence-associated secretory phenotype for cancer immunotherapy","volume":"15","author":"Wang","year":"2025","journal-title":"Acta Pharm Sin B"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.18632\/aging.102172","article-title":"The senescence-associated secretory phenotype (SASP) from mesenchymal stromal cells impairs growth of immortalized prostate cells but has no effect on metastatic prostatic cancer cells","volume":"11","author":"Alessio","year":"2019","journal-title":"Aging"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.542","article-title":"Cellular senescence in cancer: molecular mechanisms and therapeutic targets","volume":"5","author":"Jin","year":"2024","journal-title":"MedComm"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3390\/cells13151281","article-title":"Therapy-induced cellular senescence: Potentiating tumor elimination or driving cancer resistance and recurrence","volume":"13","author":"Liu","year":"2024","journal-title":"Cells"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25158448","article-title":"Therapy-induced senescence: Novel approaches for markers identification","volume":"25","author":"Pacifico","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2024.103228","article-title":"Therapy-induced senescence through the redox lens","volume":"74","author":"Robert","year":"2024","journal-title":"Redox Biol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41514-024-00138-4","article-title":"Senolytics: from pharmacological inhibitors to immunotherapies, a promising future for patients\u2019 treatment","volume":"10","author":"Lelarge","year":"2024","journal-title":"NPJ Aging"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1080\/15384101.2024.2364579","article-title":"Therapy-induced senescence is finally escapable, what is next","volume":"23","author":"Saleh","year":"2024","journal-title":"Cell Cycle"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00668-4","article-title":"Senescence and cancer - role and therapeutic opportunities","volume":"19","author":"Schmitt","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3390\/cells10071568","article-title":"Senescence and aging: Does it impact cancer immunotherapies","volume":"10","author":"Maggiorani","year":"2021","journal-title":"Cells"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.115145","article-title":"Cancer immunotherapy in elderly patients: The concept of immune senescence challenged by clinical experience","volume":"214","author":"Gu\u00e9gan","year":"2025","journal-title":"Eur J Cancer"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009462","article-title":"Impact of immunological aging on T cell-mediated therapies in older adults with multiple myeloma and lymphoma","volume":"12","author":"Ullrich","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-20-1239","article-title":"Immune checkpoint inhibitors in elderly patients treated for a lung cancer: a narrative review","volume":"10","author":"Naltet","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-024-01149-2","article-title":"Toxicity of cancer immunotherapies in older patients: Does age make a difference","volume":"41","author":"Cil","year":"2024","journal-title":"Drugs Aging"},{"key":"B67","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13046-022-02264-x","article-title":"Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity","volume":"41","author":"Archilla-Ortega","year":"2022","journal-title":"J Exp Clin Cancer Res CR"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3390\/cancers18020255","article-title":"Immunotherapeutic strategies for prostate cancer: A comprehensive review","volume":"18","author":"Flores-Islas","year":"2026","journal-title":"Cancers"},{"key":"B69","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s12967-026-07720-2","article-title":"Recent advances and future prospects of immunotherapeutic approaches in prostate cancer","volume":"24","author":"Wang","year":"2026","journal-title":"J Transl Med"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000000117","article-title":"Targeting metastatic hormone sensitive prostate cancer: Chemohormonal therapy and new combinatorial approaches","volume":"201","author":"Damodaran","year":"2019","journal-title":"J Urol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41467-024-54132-1","article-title":"Therapy-induced senescent cancer cells contribute to cancer progression by promoting ribophorin 1-dependent PD-L1 upregulation","volume":"16","author":"Hwang","year":"2025","journal-title":"Nat Commun"},{"key":"B72","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.semcancer.2024.12.001","article-title":"Immune senescence: A key player in cancer biology","volume":"108","author":"Yang","year":"2025","journal-title":"Semin Cancer Biol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1852294\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T05:40:36Z","timestamp":1784785236000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1852294\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":72,"alternative-id":["10.3389\/fimmu.2026.1852294"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1852294","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]},"article-number":"1852294"}}